- Home
- RARE vs IBOC Comparison
RARE vs IBOC Comparison
Compare RARE & IBOC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- IBOC
- Stock Information
- Founded
- RARE 2010
- IBOC 1966
- Country
- RARE United States
- IBOC United States
- Employees
- RARE N/A
- IBOC N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- IBOC Major Banks
- Sector
- RARE Health Care
- IBOC Finance
- Exchange
- RARE Nasdaq
- IBOC Nasdaq
- Market Cap
- RARE 5.2B
- IBOC 4.5B
- IPO Year
- RARE 2014
- IBOC N/A
- Fundamental
- Price
- RARE $43.98
- IBOC $64.31
- Analyst Decision
- RARE Strong Buy
- IBOC
- Analyst Count
- RARE 14
- IBOC 0
- Target Price
- RARE $88.43
- IBOC N/A
- AVG Volume (30 Days)
- RARE 717.6K
- IBOC 336.3K
- Earning Date
- RARE 02-13-2025
- IBOC 11-07-2024
- Dividend Yield
- RARE N/A
- IBOC 2.05%
- EPS Growth
- RARE N/A
- IBOC N/A
- EPS
- RARE N/A
- IBOC 6.43
- Revenue
- RARE $522,745,000.00
- IBOC $799,362,000.00
- Revenue This Year
- RARE $27.36
- IBOC N/A
- Revenue Next Year
- RARE $18.61
- IBOC N/A
- P/E Ratio
- RARE N/A
- IBOC $10.00
- Revenue Growth
- RARE 27.44
- IBOC 0.95
- 52 Week Low
- RARE $37.02
- IBOC $48.85
- 52 Week High
- RARE $60.37
- IBOC $76.91
- Technical
- Relative Strength Index (RSI)
- RARE 33.50
- IBOC 35.19
- Support Level
- RARE $41.45
- IBOC $69.68
- Resistance Level
- RARE $50.00
- IBOC $72.10
- Average True Range (ATR)
- RARE 1.83
- IBOC 1.88
- MACD
- RARE -0.31
- IBOC -1.21
- Stochastic Oscillator
- RARE 26.55
- IBOC 16.92
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About IBOC International Bancshares Corporation
International Bancshares Corp is a multibank financial holding company. The company provides commercial and retail banking services in Texas and Oklahoma. The services provided by the bank include checking, savings, bank cards, lending, insurance, mortgage, investments, and other services.